GlassScriptPhysician profile
Rohan Garje
NPI 1184902884
$11,098.61
in general payments reported to CMS, 2019-2025
18 companies · $10K in 2025
The $10K reported for 2025 was more than what 89% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $157 · 2023: $503 · 2024: $161 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,150 · Food and Beverage: $1,278 · Travel and Lodging: $415 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,150.00 |
| Food and Beverage | $1,278.33 |
| Travel and Lodging | $414.66 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $9,958.34 | 2023-2025 | |
| Exelixis INC. | $290.26 | 2022-2025 | Cabometyx |
| Pfizer INC. | $225.17 | 2023-2025 | |
| Blue Earth Diagnostics | $146.53 | 2023-2025 | Posluma |
| Seagen INC. | $121.87 | 2023 | Padcev |
| Janssen Biotech, INC. | $99.00 | 2023 | Erleada |
| Janssen Scientific Affairs, LLC | $94.41 | 2023 | Balversa |
| Merck Sharp & Dohme LLC | $68.02 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Astellas Pharma US INC | $31.77 | 2023 | Padcev |
| Daiichi Sankyo INC. | $25.62 | 2024 | Enhertu |
| Tempus Ai, INC | $20.21 | 2024 | |
| Sumitomo Pharma America, INC. | $17.41 | 2024 | Gemtesa |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rohan Garje listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.